Sub-q Testosterone Autoinjector is a safe and effective alternative method for TRT

Buy Lab Tests Online

madman

Super Moderator
Introduction: Xyosted® is a subcutaneous testosterone enanthate-autoinjector (SCTE-AI) which was approved by the Food and Drug Administration in 2018 for patient-administered weekly testosterone replacement therapy (TRT).

Objective: This is the largest non-industry sponsored post-market study to evaluate the safety and efficacy profile of SCTE-AI in outpatient urology clinics.

Methods: From January to October 2019, 110 hypogonadal men were treated with SCTE-AI at a two-institutions. Patients were assessed in a pre-therapy visit prior to receiving SCTE-AI and re-assessed at 6-weeks after treatment initiation. Patients with a history of prostate cancer were excluded. Trough serum total testosterone (TT), estradiol, prostate-specific antigen (PSA), and hematocrit (HCT) levels were collected at clinic visits. Therapeutic phlebotomy was recommended for HCT>54%, and treatment was discontinued for significant increases in PSA and for significant treatment-related adverse events. Values from each visit were compared with univariate analysis.

Results: 110 patients completed the 6 weeks of observation with a mean age of 40.3 ± 10.5. TT significantly rose from 246.6 ± 113.3 ng/dL pretherapy to 538.4 ± 209.3 ng/dL at 6 weeks, p<0.001. Post-therapy, 101/110 (91.8%) of patients had TT>300 ng/dL (Table). No patients had HCT > 54%. 74 patients (70.5%) had PSA increase with only 3 (2.9%) experiencing an increase >1.0. There was a significant increase in mean PSA from 1.07 ± 0.8 pretherapy to 1.18 ± 0.9 at 6 weeks, p= 0.01. One patient had immediate treatment cessation following the discovery of prostate cancer.

Conclusions: This is the largest non-industry sponsored safety and efficacy profile of SCTE-AI application in urology clinics. After 6 weeks of observation, TT levels increased significantly. SCTE-AI is a safe and effective alternative method for TRT.



Table: Total Testosterone (TT) ranges before and after 6 weeks of SCTE-AI therapy

     
 

Pre-Therapy

6 weeks

  

TT (ng/dL)

n

%

n

%

0-300

96

87.3%

9

8.2%

300-1000

14

12.7%

97

88.2%

>1000

0

0.0%

4

3.6%

 
Defy Medical TRT clinic doctor

madman

Super Moderator
Post-Market Safety and Efficacy Profile of Subcutaneous Testosterone Enanthate-Autoinjector (2020)



Choi, E; Xu, P; Loeb, C; El-Khatib, F; Yafi, F; Kavoussi, P
Screenshot (2752).png

Screenshot (2753).png

Screenshot (2754).png

Screenshot (2755).png

Screenshot (2756).png

Screenshot (2757).png

Screenshot (2758).png
 

madman

Super Moderator
The myth needs to be put to rest that injecting T sub-q is inferior to IM when it comes to absorption/effectiveness for F**K S**E!
Screenshot (2759).png
 

madman

Super Moderator
*This is the largest non-industry sponsored post-market study to evaluate the safety and efficacy profile of SCTE-AI in outpatient urology clinics
 
Buy Lab Tests Online

Sponsors

bodybuilder test discounted labs
Defy Medical TRT clinic
nelson vergel coaching for men
Discounted Labs
TRT in UK Balance my hormones
Testosterone books nelson vergel
Register on ExcelMale.com
Trimix HCG Offer Excelmale
Thumos USA men's mentoring and coaching
Testosterone TRT HRT Doctor Near Me
how to save your marriage

Online statistics

Members online
1
Guests online
7
Total visitors
8

Latest posts

Top